Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis
Tóm tắt
The failure of current Standard Short-Course Chemotherapy (SCC) in new and previously treated cases with tuberculosis (TB) was mainly due to drug resistance development. But little is known on the characteristics of acquired drug resistant TB during SCC and its correlation with SCC failure. The objective of the study is to explore the traits of acquired drug resistant TB emergence and evaluate their impacts on treatment outcomes. A prospective observational study was performed on newly admitted smear positive pulmonary TB (PTB) cases without drug resistance pretreatment treated with SCC under China’s National TB Control Program (NTP) condition from 2008 to 2010. Enrolled cases were followed up through sputum smear, culture and drug susceptibility testing (DST) at the end of 1, 2, and 5 months after treatment initiation. The effect factors of early or late emergence of acquired drug resistant TB , such as acquired drug resistance patterns, the number of acquired resistant drugs and previous treatment history were investigated by multivariate logistic regression; and the impact of acquired drug resistant TB emergence on treatment failure were further evaluated. Among 1671 enrolled new and previously treated cases with SCC, 62 (3.7 %) acquired different patterns of drug resistant TB at early period within 2 months or later around 3–5 months of treatment. Previously treated cases were more likely to develop acquired multi-drug resistant TB (MDR-TB) (OR, 3.8; 95 %CI, 1.4–10.4; P = 0.015). Additionally, acquired MDR-TB cases were more likely to emerge at later period around 3-5 months after treatment starting than that of non-MDR-TB mainly appeared within 2 months (OR, 8.3; 95 %CI, 1.7–39.9; P = 0.008). Treatment failure was associated with late acquired drug resistant TB emergence (OR, 25.7; 95 %CI, 4.3–153.4; P < 0.001) with the reference of early acquired drug resistant TB emergence. This study demonstrates that later development of acquired drug resistant TB during SCC is liable to suffer treatment failure and acquired MDR-TB pattern may be one of the possible causes.
Tài liệu tham khảo
World Health Organization. Global tuberculosis report 2013. Geneva: WHO; 2013. WHO/HTM/TB/ 2013. 11.
World Health Organization. Treatment of tuberculosis guidelines. 4th ed. Geneva: WHO; 2010. WHO/HTM/STB/2009.420.
Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10):S231–79.
Hong Kong Chest Service; British Medical Research Council. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Tubercle. 1982;63(2):89–98.
Service HKC, Council BMR. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary of isoniazid, rifampicin, and pyrazinamide: results at 30 months. Am Rev Respir Dis. 1991;143(4):700–6.
Service ST, Council BMR. Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis. 1985;132(2):374–8.
Council K-Z-BMR. Controlled clinical trial of levamisole in short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis. 1989;140(4):990–5.
Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migiori GB, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA. 2000;283(19):2537–45.
World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: WHO; 2014. WHO/ HTM/ TB/ 2014. 11.
World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Geneva: WHO; 2003. WHO/CDS/TB/2003.313.
Enarson DA, Rieder HL, Arnadottir T, Trebucq A. Management of tuberculosis: a guide for low income countries. 5th ed. Paris: International Union Against Tuberculosis and Lung Disease; 2000.
Mak A, Thomas A, Del Granado M, Zaleskis R, Mouzafarova N, Menzies D. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med. 2008;178(3):306–12.
Ministry of Health. Guidelines for implementing the national tuberculosis control program in China. Beijing: Peking Union Medical College Press; 2008.
Liu Y, Jiang G, Zhao L, Fu Y, Li Y, Bi Z, et al. Drug resistance of mycobacterium tuberculosis in a nationwide epidemiological survey in China in the year of 2000. Zhonghua Jie He He Hu Xi Za Zazhi. 2002;25(4):224–7.
Kent P, Kubica G. Public health mycobacteriology: a guide for the level III laboratory. Atlanta: Centers for Disease Control; 1985.
Han T. Effectiveness of standard short-course chemotherapy for treating tuberculosis and the impact of drug resistance on its outcome. Int J Evid Based Healthc. 2006;4(2):101–17.
Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012;366(23):2161–70.
Tang S, Tan S, Yao L, Li F, Li L, Guo X, et al. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation. PLoS ONE. 2013;8(12):e82943.
Liu Q, Zhu L, Shao Y, Song H, Li G, Zhou Y, et al. Rates and risk factors for drug resistance tuberculosis in Northeastern China. BMC Public Health. 2013;13:1171–7.
Rifat M, Milton AH, Hall J, Oldmeadow C, Islam MA, Husain A, et al. Development of multidrug resistant tuberculosis in Bangladesh: a case-control study on risk factors. PLoS ONE. 2014;9(8):e105214.
Zhao P, Li XJ, Zhang SF, Wang XS, Liu CY. Social behaviour risk factors for drug resistant tuberculosis in mainland China: a meta-analysis. J Int Med Res. 2012;40(2):436–45.
Espinal MA, Laserson K, Camacho M, Fusheng Z, Kim SJ, Tlali RE, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis. 2001;5(10):887–93.
Matthys F, Rigouts L, Sizaire V, Vezhnina N, Lecoq M, Golubeva V, et al. Outcomes after chemotherapy with WHO category IIregimen in a population with high prevalence of drug resistant tuberculosis. PLoS ONE. 2009;4(11):e7954.
Seung KJ, Gelmanova IE, Perementin GG, Golubchikova VT, Pavlova VE, Sirotkina OB, et al. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis. 2004;39(9):1321–8.
Anuwatnonthakate A, Whitehead SJ, Varma JK, Silachamroon U, Kasetjaroen Y, Moolphate S, et al. Effect of mycobacterial drug resistance patterns on patient’ survival: a cohort study in Thailand. Glob J Health Sci. 2013;5(6):60–72.
Choi H, Lee M, Chen RY, Kim Y, Yoon S, Joh JS, et al. Predictors of pulmonary tuberculosis treatment outcomes in South Korea: a prospective cohort study, 2005–2012. BMC Infect Dis. 2014;14:360.
Chang KC, Leung CC, Yew WW, Ho SC, Tam CM. A nested case-control study on treatment-related risk factor for early relapse of tuberculosis. Am J Respir Crit Care Med. 2004;170(10):1124–30.
Seyoum B, Demissie M, Worku A, Bekele S, Aseffa A. Prevalence and drug resistance patterns of mycobacterium tuberculosis among new smear positive pulmonary tuberculosis patients in eastern Ethiopia. Tuberc Res Treat. 2014;2014:753492.
Jordan TS, Davies PD. Clinical tuberculosis and treatment outcomes. Int J Tuberc Lung Dis. 2009;14(6):683–8.
Hu Y, Jiang WL, Wang WB, Xu B. A-cohort study on the standard short-course chemotherapy program for drug resistant tuberculosis in the rural counties in Eastern China. Zhonghua Liu Xing Bing Xue Za Zhi. 2008;29(6):540–4.
Bang D, Andersen PH, Andersen AB, Thomsen V. Isoniazid-resistant tuberculosis in Denmark: mutations, transmission and treatment outcome. J Infect. 2010;60(6):452–7.
Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis. 2011;53(4):369–72.
Reed GW, Choi H, Lee SY, Lee M, Kim Y, Park H, et al. Impact of diabetes and smoking on mortality in tuberculosis. PLoS ONE. 2013;8(2):e58044.
Kolappan C, Gopi PG. Tobacco smoking and pulmonary tuberculosis. Thorax. 2002;57(11):964–6.
Maciel EL, Brioschi AP, Peres RL, Guidoni LM, Ribeiro FK, Hadad DJ, et al. Smoking and 2-month culture conversion during anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2013;17(2):225–8.
Franke MF, Appleton SC, Bayona J, Arteaga F, Palacios E, Llaro K, et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis. 2008;46(12):1844–51.
Faustini A, Hall A, Perucci C. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006;61(2):158.
Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, et al. Impact of extensive drug resistance on treatment outcomes in Non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007;45(10):1290–5.
Dalton T, Cegielski P, Akksilp S, Asencios L, Campos Caoili J, Cho SN, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet. 2012;380(9851):1406–17.
Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med. 2008;149(2):123–34.
Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, et al. Standardized treatment of active tuberculosis in patients with previous treatment and /or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med. 2009;6(9), e1000150.
Yoshiyama T, Yanai H, Rhiengtong D, Palittapongarnpim P, Nampaisan O, Supawitkul S, et al. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Int J Tuberc Lung Dis. 2004;8(1):31–8.
Wallis RS, Kim P, Cole S, Hanna D, Andrade BB, Maeurer M, et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis. 2013;13(4):362–72.